Avalyn Pharma AVLN

Avalyn Pharma Inc. is a clinical stage biopharmaceutical company that develops inhaled therapies for serious rare respiratory diseases. Its lead product candidates are optimized inhaled formulations of pirfenidone and nintedanib aimed at treating pulmonary fibrosis and related interstitial lung disorders. The company uses a proprietary nebulizer platform to deliver drug directly to the lungs while limiting systemic exposure. Avalyn Pharma Inc. seeks to improve efficacy and tolerability compared with existing oral antifibrotic treatments. The pipeline includes AP01 an inhaled pirfenidone formulation for progressive pulmonary fibrosis, AP02 an inhaled nintedanib formulation for idiopathic pulmonary fibrosis and AP03 a fixed dose combination of inhaled pirfenidone and nintedanib. These candidates are being evaluated in clinical trials ranging from Phase 1 to Phase 2b. The company believes that delivering antifibrotic agents via inhalation can achieve higher lung concentrations with lower systemic exposure.

Avalyn Pharma Inc. has not yet received approval for any product and therefore does not generate revenue from drug sales. The company finances its operations primarily through equity capital raised from investors. As disclosed in the filing, Avalyn Pharma Inc. has raised approximately $389 million in equity capital since inception. In addition to equity financing, the company is party to a license agreement with PARI that provides for upfront payments, milestone payments and royalties on net sales of licensed products. These contractual payments could become a source of revenue if development milestones are achieved and products are commercialized. Future revenue is expected to come from the commercialization of its inhaled therapeutic candidates once they obtain regulatory clearance.

Avalyn Pharma Inc. competes in the pulmonary fibrosis segment of the broader respiratory disease market. The current standard of care consists of three approved oral antifibrotic agents: pirfenidone marketed as ESBRIET by Legacy Pharma Inc. and Genentech/Roche, nintedanib marketed as OFEV by Boehringer Ingelheim, and nerandomilast marketed as JASCAYD by Boehringer Ingelheim. In addition to these established therapies, numerous biopharmaceutical companies are developing novel mechanisms of action for pulmonary fibrosis, including United Therapeutics, Insmed, Celea Therapeutics, Vicore Pharma, Endeavor Biomedicines, Contineum Therapeutics, Eli Lilly and Company in collaboration with Mediar Therapeutics, Insilico Medicine, MannKind, Syndax Pharmaceuticals, Roche, Calluna Pharma and Rein Therapeutics. Avalyn Pharma Inc. differentiates itself through its exclusive license to the PARI eRapid nebulizer system that uses eFlow Technology for drug delivery. The company has built a robust intellectual property portfolio covering drug compositions formulations and drug device combinations with issued patents extending beyond 2035 and pending applications that may extend protection beyond 2040. These protections create high technical and regulatory barriers to entry that support a durable competitive advantage. The company’s focus on inhaled delivery aims to improve lung exposure while reducing systemic side effects, a potential advantage over existing oral therapies. Avalyn Pharma Inc. also points to the experience of its management team, which includes former leaders from organizations that brought products such as BREZTRI, BEVESPI, XOLAIR, TOBI and BAXDELA to market. This deep expertise in inhaled drug development and commercialization further strengthens its position relative to competitors.

Avalyn Pharma Inc. intends to serve patients suffering from pulmonary fibrosis and related interstitial lung diseases. Its therapies are designed for use in clinical settings such as hospitals, specialty clinics and physician offices. The company also engages with health care providers and payers to support adoption of its inhaled products once they receive regulatory approval. Avalyn Pharma Inc. works closely with clinical trial sites and investigators to generate the data needed for regulatory submissions. Patient advocacy groups and medical societies are additional stakeholders that inform the company’s understanding of disease burden and treatment needs. No specific customer names are disclosed in the filing.